6-((R)-3-tert-Butoxycarbonylamino-pyrrolidin-1-yl)-5-fluoro-3-oxo-3H-7-oxa-13b-aza-benzo[hi]chrysene-2-carboxylic acid | 1056127-89-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 6-((R)-3-tert-Butoxycarbonylamino-pyrrolidin-1-yl)-5-fluoro-3-oxo-3H-7-oxa-13b-aza-benzo[hi]chrysene-2-carboxylic acid
• 英文别名: 15-fluoro-14-[(3R)-3-[(2-methylpropan-2-yl)oxycarbonylamino]pyrrolidin-1-yl]-18-oxo-12-oxa-1-azapentacyclo[11.7.1.02,11.05,10.017,21]henicosa-2(11),3,5,7,9,13(21),14,16,19-nonaene-19-carboxylic acid
• CAS: 1056127-89-9
• 化学式: C₂₉H₂₆FN₃O₆
• 分子量: 531.54
• InChiKey: LDMXUQYNKZCYGI-MRXNPFEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  39
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  108
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  6-((R)-3-tert-Butoxycarbonylamino-pyrrolidin-1-yl)-5-fluoro-3-oxo-3H-7-oxa-13b-aza-benzo[hi]chrysene-2-carboxylic acid 在 盐酸 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 6-((R)-3-Amino-pyrrolidin-1-yl)-5-fluoro-3-oxo-3H-7-oxa-13b-aza-benzo[hi]chrysene-2-carboxylic acid; hydrochloride
  参考文献：
  名称：

  Design of New Topoisomerase II Inhibitors Based upon a Quinobenzoxazine Self-Assembly Model

  摘要：

  A new class of pyridobenzophenoxazine compounds has been developed as topoisomerase II inhibitors for anticancer chemotherapy. These compounds were designed based on a proposed model of a quinobenzoxazine self-assembly complex on DNA. They showed excellent inhibitory effects on several tumor cell lines with nanomolar IC50 values. Their cytotoxic potency correlates with their ability to unwind DNA and inhibit topoisomerase II.

  DOI：

  10.1021/jm980265c
• 作为产物：
  描述：

  ethyl 1,2-difluoro-4-oxo-4H-pyrido[3,2,1-kl]benzo[f]-phenoxazine-5-carboxylate 在 吡啶 、 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 36.5h， 生成 6-((R)-3-tert-Butoxycarbonylamino-pyrrolidin-1-yl)-5-fluoro-3-oxo-3H-7-oxa-13b-aza-benzo[hi]chrysene-2-carboxylic acid
  参考文献：
  名称：

  Design of New Topoisomerase II Inhibitors Based upon a Quinobenzoxazine Self-Assembly Model

  摘要：

  A new class of pyridobenzophenoxazine compounds has been developed as topoisomerase II inhibitors for anticancer chemotherapy. These compounds were designed based on a proposed model of a quinobenzoxazine self-assembly complex on DNA. They showed excellent inhibitory effects on several tumor cell lines with nanomolar IC50 values. Their cytotoxic potency correlates with their ability to unwind DNA and inhibit topoisomerase II.

  DOI：

  10.1021/jm980265c

文献信息

• SUBSTITUTED QUINOBENZOXAZINE ANALOGS
  申请人：Whitten Jeffrey P.

  公开号：US20080261963A1

  公开（公告）日：2008-10-23

  The present invention relates to quinobenzoxazines analogs having the general formula: and pharmaceutically acceptable salts, esters and prodrugs thereof; wherein A, U, V, W, X and Z are substituents. The present invention also relates to methods for using such compounds.

  本发明涉及具有以下一般式的喹诺苯并噁唑类似物，以及其药学上可接受的盐、酯和前药： 其中A、U、V、W、X和Z是取代基。本发明还涉及使用这些化合物的方法。
• Substituted quinobenzoxazine analogs
  申请人：Whitten P. Jeffrey

  公开号：US20070043039A1

  公开（公告）日：2007-02-22

  The present invention relates to methods for ameliorating a cell proliferative disorder using quinobenzoxazines analogs having the general formula: and pharmaceutically acceptable salts, esters and prodrugs thereof; wherein A, U, V, W, X and Z are substituents.

  本发明涉及使用具有以下通式的喹诺苯并噁唑类似物以及其药学上可接受的盐、酯和前药，来改善细胞增殖性疾病的方法；其中A、U、V、W、X和Z是取代基。
• US7326702B2
  申请人：——

  公开号：US7326702B2

  公开（公告）日：2008-02-05
• US7354916B2
  申请人：——

  公开号：US7354916B2

  公开（公告）日：2008-04-08
• US7381720B2
  申请人：——

  公开号：US7381720B2

  公开（公告）日：2008-06-03